Georg Härter REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 GEORG HÄRTER, University Hospital, Ulm For patients with multiple myeloma b
Georg Härter
REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007GEORG HÄRTER, University Hospital, UlmFor patients with multiple myeloma being treated with the proteasome inhibitor bortezomib, doctor’s should be wary of viral reactivation – and they should give antiviral prophylaxis in all cases. This finding was unveiled at ICAAC byGeorg Härterfrom the University Hospital in Ulm, and he shared his data with Derek Thorne.
Related Episodes
Audio Journal of Oncology Volume 16 Number 9
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Emiel Rutgers, Netherlands Cancer Institute, Amsterdam Angel Rod
New Targets Bring Promise For Lung Cancer Therapy
Egbert Smit EGBERT SMIT, Free University of Amsterdam There are a number of promising new molecular targets for lung cancer chemotherapy which were discussed at the Turin congress by Egbert Smit. He t
Target Angiogenesis for Lung Cancer With Multiple Tyrosine Kinase Inhibitors
Silvia Novello SILVIA NOVELLO, University of Turin Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello w